<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Adicet Bio Inc — News on 6ix</title>
    <link>https://6ix.com/company/adicet-bio-inc</link>
    <description>Latest news and press releases for Adicet Bio Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 12 Mar 2026 20:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/adicet-bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683541dc78dffbe2df0e109e.webp</url>
      <title>Adicet Bio Inc</title>
      <link>https://6ix.com/company/adicet-bio-inc</link>
    </image>
    <item>
      <title>Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress-2</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress-2</guid>
      <pubDate>Thu, 12 Mar 2026 20:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., March 12, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025.</description>
    </item>
    <item>
      <title>Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-present-guggenheim-emerging-120000197</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-present-guggenheim-emerging-120000197</guid>
      <pubDate>Fri, 30 Jan 2026 12:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., January 30, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.</description>
    </item>
    <item>
      <title>Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-provides-corporate-highlights-120000655</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-provides-corporate-highlights-120000655</guid>
      <pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., January 07, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026.</description>
    </item>
    <item>
      <title>Adicet Bio Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-reverse-stock-133000194</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-reverse-stock-133000194</guid>
      <pubDate>Fri, 26 Dec 2025 13:30:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., December 26, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet’s common stock, par value $0.0001 per share.</description>
    </item>
    <item>
      <title>Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-inducement-grant-192300626</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-inducement-grant-192300626</guid>
      <pubDate>Fri, 28 Nov 2025 19:23:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., November 28, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025.</description>
    </item>
    <item>
      <title>MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/maxcyte-reports-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/maxcyte-reports-third-quarter-2025-financial-results-and-reiterates-full-year-2025-revenue-guidance</guid>
      <pubDate>Wed, 12 Nov 2025 21:05:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance. Third Quarter and Recent Highlights Core business revenue of $6.4 million in the third quarter of 2025.Strategic Platform Lic</description>
    </item>
    <item>
      <title>Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-third-quarter-210100090</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-third-quarter-210100090</guid>
      <pubDate>Wed, 05 Nov 2025 21:01:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., November 05, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2025.</description>
    </item>
    <item>
      <title>Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-inducement-grants-205900343</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-inducement-grants-205900343</guid>
      <pubDate>Fri, 31 Oct 2025 20:59:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., October 31, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on October 31, 2025.</description>
    </item>
    <item>
      <title>Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-110000250</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-110000250</guid>
      <pubDate>Tue, 28 Oct 2025 11:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., October 28, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.</description>
    </item>
    <item>
      <title>Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-first-patient-110000089</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-first-patient-110000089</guid>
      <pubDate>Thu, 16 Oct 2025 11:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., October 16, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first patient has been dosed in its Phase 1 clinical trial evaluating ADI-001 in treatment-refractory RA.</description>
    </item>
    <item>
      <title>Adicet Bio, Inc. Announces $80 Million Registered Direct Offering</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-inc-announces-80-110100140</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-inc-announces-80-110100140</guid>
      <pubDate>Tue, 07 Oct 2025 11:01:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, October 07, 2025--Adicet Bio, Inc. (&quot;Adicet&quot;) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten registered direct offering of 70,001,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,000,000 shares of common stock. The shares of common stock are b</description>
    </item>
    <item>
      <title>Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-positive-preliminary-104500604</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-positive-preliminary-104500604</guid>
      <pubDate>Tue, 07 Oct 2025 10:45:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, October 07, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase 1 study evaluating ADI-001 as a potential treatment for patients with autoimmune diseases. The data cut as of August 31, 2025, includes seven patients (five</description>
    </item>
    <item>
      <title>Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-present-h-c-110000075</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-present-h-c-110000075</guid>
      <pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, September 02, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York.</description>
    </item>
    <item>
      <title>Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-second-quarter-200100901</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-second-quarter-200100901</guid>
      <pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, August 07, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2025.</description>
    </item>
    <item>
      <title>MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/maxcyte-reports-second-quarter-2025-financial-results-and-updates-full-year-2025-guidance</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/maxcyte-reports-second-quarter-2025-financial-results-and-updates-full-year-2025-guidance</guid>
      <pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
      <description>ROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its second quarter ended June 30, 2025 financial results and updated its 2025 guidance. Second Quarter and Recent Highlights Core business revenue of $8.2 million in the second quarter of 2025, an increase of 8% over the</description>
    </item>
    <item>
      <title>Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-110000466</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-110000466</guid>
      <pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, August 05, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston.</description>
    </item>
    <item>
      <title>MaxCyte Signs Platform License Agreement with Adicet Bio</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/maxcyte-signs-platform-license-agreement-with-adicet-bio</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/maxcyte-signs-platform-license-agreement-with-adicet-bio</guid>
      <pubDate>Mon, 04 Aug 2025 12:05:00 GMT</pubDate>
      <description>MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support development of Adicet’s gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced it has signed a strategic platform license (SPL) with Adicet Bio, I</description>
    </item>
    <item>
      <title>Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-first-systemic-110000226</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-announces-first-systemic-110000226</guid>
      <pubDate>Thu, 24 Jul 2025 11:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, July 24, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (SSc) patient has been dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases.</description>
    </item>
    <item>
      <title>Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-200000488</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-participate-fireside-chat-200000488</guid>
      <pubDate>Wed, 21 May 2025 20:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, May 21, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference being held from June 3-5, 2025 in New York.</description>
    </item>
    <item>
      <title>Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-first-quarter-200100218</link>
      <guid isPermaLink="true">https://6ix.com/company/adicet-bio-inc/news/adicet-bio-reports-first-quarter-200100218</guid>
      <pubDate>Tue, 06 May 2025 20:01:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif. &amp; BOSTON, May 06, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the first quarter ended March 31, 2025.</description>
    </item>
  </channel>
</rss>